Biotech Deals by the Numbers
Executive Summary
Big pharma-biotech dealmaking continues to increase in popularity and price--companies with later-stage products are finding they truly can drive better deals. Meanwhile, drug companies are increasingly paying for their dealmaking with equity, as they leverage their balance sheet to offset research expenses.
You may also be interested in...
Licensing Trends By Clinical Phase
We revisit a chart from 1997 examining deal volume by clinical phase to highlight the changing landscape of late stage licensing.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”